Related Experiment Video

Updated: Feb 25, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Principles of Anticoagulation and New Therapeutic Agents in Atrial Fibrillation

Pamela S N Goldman1, Michael D Ezekowitz

  • 1Lankenau Institute for Medical Research, Clinical Research Center, 100 Lancaster Avenue, Wynnewood, PA 19096, USA.

Cardiac Electrophysiology Clinics
|August 4, 2017
PubMed

Insights

Anticoagulation is crucial for cardiac arrhythmias like atrial fibrillation (AF) and atrial flutter to prevent thromboembolism. This review covers anticoagulation principles and agents for managing these conditions.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Anticoagulation is essential for patients with cardiac arrhythmias, such as atrial fibrillation (AF) and atrial flutter, to mitigate thromboembolic risks.
  • AF affects approximately 2 million people in the U.S., with projections indicating over 10 million by 2050.
  • Warfarin has demonstrated a 68% reduction in stroke risk for AF patients, though it carries inherent risks.

Purpose of the Study:

  • To review the fundamental principles of anticoagulation in cardiac arrhythmias.
  • To discuss the mechanisms of action, pharmacologic profiles, and developmental stages of anticoagulant therapies.

Main Methods:

  • Literature review focusing on anticoagulation principles and therapeutic agents.
  • Analysis of existing data on warfarin efficacy and risks in AF management.
  • Examination of current and emerging anticoagulant drugs.

Main Results:

  • Anticoagulation strategies for AF and atrial flutter share similar principles due to the nature of the arrhythmias.
  • Warfarin is a highly effective agent for reducing stroke risk in AF.
  • Antithrombotic therapy, including anticoagulants and antiplatelets, is recommended for the majority of AF patients.

Conclusions:

  • Effective anticoagulation is a cornerstone in managing atrial fibrillation and atrial flutter.
  • Understanding the pharmacologic profiles and development of anticoagulants is key for optimizing patient care.
  • Continued research into novel anticoagulant agents is vital for improving outcomes and safety.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K
Robotic Ablation of Atrial Fibrillation11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

20.3K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
400
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.5K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
544